The event, hosted by the UofL , honored faculty and staff from five schools and colleges for accomplishments in developing new technologies, working with industry and launching research-backed startups.

“We like to say ���Ǵڳ�’s ‘igniting innovation’ — and that’s absolutely true,” said president Kim Schatzel, giving opening remarks at the event. “Since joining the UofL community, I’ve seen that our campus is full-to-bursting with creativity and ideas, some with the power to transform the way we live and work. If UofL is igniting innovation, our innovators are the spark, and the work they do has a lasting and positive impact here on our campus and well beyond.”

Six major awards were also presented, including Innovator of the Year. This year, that honor went to School of Medicine researcher Nobuyuki Matoba, recognized for his work to tackle devastating diseases, inflammatory bowel disease and cancer, through groundbreaking new vaccines, immunotherapeutics and treatments that leverage protein engineering and plant-based biotechnology.����

In addition to Matoba, major awards were also presented to:��

• • Dan Popa, of the J.B. Speed School of Engineering, who won the Catalyst Award for his work to build an environment that encourages innovation at the Louisville Automation and Robotics Research Institute (LARRI);
  • Geoff Clark, Joe Burlison and Kenneth Palmer, of the School of Medicine, who won the Industry Partnership Award for their longstanding commercialization relationship with Qualigen Therapeutics;��
  • Cheri Levinson and Christina Ralph-Nearman, of the College of Arts and Sciences, who won a Trailblazer Award for their work to develop novel virtual reality and personalized treatment tools for eating disorders and launch a startup, Awaken Digital Health Solutions, to drive them to market;
  • Kunal Kate, of the J.B. Speed School of Engineering, who won a Trailblazer Award in part for his work with the Kentucky MBDA Advanced Manufacturing Center to help minority-owned businesses leverage cutting-edge technology;��
  • Noppadon Sathitsuksanoh, of the J.B. Speed School of Engineering, who won the night’s final Trailblazer Award for his work to develop new ways of producing sustainable fuels and chemicals from waste materials;

Over the past two years, 57 of the honorees earned new patents, 28 had their technology optioned or licensed to a company and 68 were awarded innovation grants, such as or , aimed at driving technologies to market. In the past fiscal year, the work of these innovators led to one new startup, 319 agreements, 49 new patents and $15.6 million in innovation-related income.

UofL Executive Vice President for Research and Innovation Kevin Gardner, whose office organizes the event, said those numbers represent real-world impact — and more, impact that can save and improve lives.��

“The innovations our researchers are developing have the potential to diagnose, treat and cure disease and overall make the way we live and work better,” he said. “What we celebrate reflects what we value as an institution — and with awards like these, we show that we value entrepreneurship and innovation.”

The event, hosted by the , honored UofL faculty and staff nominated by their colleagues or self-nominated for outstanding research and scholarship accomplishments in fiscal year 2021.

“I often say that UofL is a true research engine, continuously blazing new trails and seeking answers to important questions,” said Interim President Lori Stewart Gonzalez, speaking at the event. “Our researchers, scholars and research administrators are the very backbone of that work and they deserve this celebration and recognition.”��

In addition to the roughly 90 recognized, six major awards were presented to:��

• • Kenneth Palmer, of the School of Medicine, who won Researcher of the Year, in part, for work to address the global COVID-19 pandemic, securing $8.5 million from the Department of Defense to adapt a novel broad-spectrum antiviral as a coronovirus-fighting nasal spray;
  • Hui Wang, of the J.B. Speed School of Engineering, who won Emerging Researcher of the Year for work to advance solid ion conductors and electrochemical energy storage;��
  • Becky Antle, of the Kent School of Social Work, who won Collaborator of the Year for serving as an evaluator on numerous groundbreaking projects with principal investigators across the university;
  • Monica Wendel, of the School of Public Health and Information Sciences, who won the Grand Challenger Award in Empowering our Communities in part for work to launch a new Health Equity Innovation Hub at UofL, backed by Humana Inc. and the Humana Foundation;
  • Shirish Barve, of the School of Medicine, who won the Grand Challenger Award in Advancing our Health for work to uncover the connections and impacts of alcohol on the body and organ injury and studying the gut/brain axis in HIV and aging; and
  • Joshua Spurgeon, of the J.B. Speed School of Engineering, who won the Grand Challenger Award in Engineering our Future Economy for work to create clean fuels using just water, carbon dioxide and sunlight, paving the way for more low-carbon power.

In addition to presenting awards, the event also highlighted the Office of Research and Innovation’s recently launched Ascending Star Fellowship program, which provides mentorship, funding and other support to high-performing associate professors. The inaugural class includes Cheri Levinson, Brandon McCormack and Kaila Story, all from the College of Arts and Sciences.��

Kevin Gardner, ���Ǵڳ�’s Executive Vice President for Research and Innovation, said his office launched this inaugural awards event to recognize faculty and staff for their contributions to ���Ǵڳ�’s research and scholarship.��

In the past fiscal year, their work helped bring in record $201.5 million to support groundbreaking work that saves and improves lives and shapes our society and culture.��And, UofL recently received another consecutive Research-1 designation from the , placing it among just 4% of schools considered.��

“What we celebrate and recognize reflects our values as an organization and as a community of scholars,” Gardner said. “Each researcher, scholar and administrator being celebrated is absolutely critical to our important work here at UofL, and we want you to know your efforts are appreciated.”

The study, published Jan. 20 in , found CBD showed a significant negative association with SARS-CoV-2 positive tests in a national sample of medical records of patients taking the FDA-approved drug for treating epilepsy. The researchers now say that clinical trials should be done to determine whether CBD could eventually be used as a preventative or early treatment for COVID-19.

They caution, however, that the COVID-blocking effects of CBD come only from a high purity, specially formulated dose taken in specific situations. The study’s findings do not suggest that consuming commercially available products with CBD additives that vary in potency and quality can prevent COVID-19.

Scientists have been looking for new therapies for people infected by the coronavirus and emerging variants, especially those who lack access to vaccines, as the pandemic continues across the country and world and as breakthrough infections become more common.

“The Commonwealth of Kentucky has a robust hemp agriculture, so we were pleased to find that pharmaceutical grade CBD is worth testing in future human clinical studies,” said Kenneth Palmer, study coauthor who headed the UofL research team. “In response to the COVID-19 pandemic, our team developed expertise in SARS-CoV-2 infection models and we welcomed the opportunity to collaborate with the University of Chicago team to confirm the efficacy of CBD treatment against SARS-CoV-2.”

Palmer is director of the Center for Predictive Medicine for Biodefense and Emerging Infectious Diseases and the Leona M. and Harry B. Helmsley Charitable Trust Endowed Chair in Plant-based Pharmaceutical Research at UofL. The center houses the Regional Biocontainment Laboratory, one of only 12 regional and two national biocontainment labs in the United States and the only one in Kentucky. Established with support from the NIH to conduct research with infectious agents, the lab includes Biosafety Level 3 facilities built to the most exacting federal safety and security standards.

Researchers from the University of Louisville co-authoring the study with Palmer are Divayasha Saxena, Jon D. Gabbard, Jennifer K. Demarco, William E. Severson and Charles D. Anderson. The research was directed by the University of Chicago and other scientists involved are from the National Argonne Laboratory, the University of Illinois at Chicago and the National COVID Cohort Collaborative Consortium.

For more detail on how medical-grade CBD shows promise as a treatment for COVID-19, check out the full story here.��

has provided a grant of $750,000 to the Co-Immunity Project — a collaboration between the University of Louisville Christina Lee Brown Envirome Institute and the Louisville Healthcare CEO Council with Louisville’s three major health systems, Baptist Health, Norton Healthcare and UofL Health. The innovative project, , identifies where the virus is found in a given community, how strong it is, and how it’s moving geographically

Phase I focuses on Louisville’s health care community and began its comprehensive coronavirus and antibody testing for health care workers with the Louisville health systems on May 4 week. All testing is conducted at the individual hospitals, and health system workers interested in participating should register in advance on the project website, .

The early funding from the JHFE, along with additional donations the project is seeking, means researchers with the initiative won’t lose valuable time in getting underway, said UofL Vice President for University Advancement Brad Shafer. “Time is of the essence with COVID-19, and this investment from JHFE, a consistent and integral partner of UofL, is enabling the university, the Louisville Healthcare CEO Council and our health care partners to initiate this important work without delay,” Shafer said.

“The Co-Immunity Project is a critically important study that will help researchers develop an understanding of this virus and its prevalence in our community,” said JHFE Board Chair Linda Schuster. “As scientists around the world focus on developing effective treatments and ultimately a vaccine, It is more important than ever for the public and private sectors to work together to support this vital work.��

“We have a long history of collaborating with the University of Louisville on medical research studies and we’re proud to partner with the Christina Lee Brown Envirome Institute and the Louisville Healthcare CEO Council on the first phase of The Co-Immunity Project.”

The Co-Immunity Project’s goal is to develop a real-time picture of the virus so decision makers can reopen Kentucky facilities safely and keep the public protected from a second wave of COVID-19. Beyond currently available diagnostic tests, the project also leverages cutting-edge antibody testing available at UofL to determine how much immunity was generated by such exposure, and to identify those with the best immune responses as donors of high-quality plasma for treating patients with advanced COVID-19.

The three-step antibody testing to understand and make use of patient immunity runs through the UofL Center for Predictive Medicine for Biodefense and Emerging Infectious Diseases (CPM), which has established a high-throughput, real-time assay for antibodies from SARS-CoV-2, the coronavirus variant that causes COVID-19. This comprehensive testing program identifies people with antibodies, their levels and quality, and tracks the evolution of the participants’ immunity. The CPM will utilize its Regional Biocontainment Laboratory, one of just 12 such facilities in the United States and the only one in Kentucky, to test for the neutralizing activity of the antibodies.

Scientists from across the globe will have access to the resulting anonymized data for future study on the effectiveness of antibody therapy. The data also may be used to better identify individuals who are better able to fight off the coronavirus and may have immunity from contracting the disease so decision-makers can reopen facilities safely and keep the public protected from a second wave of COVID-19.��

Following Phase I testing of Louisville hospital workers, the next phases will expand testing to workers in long-term care facilities, and then to the general public. Participants can help in this crucial work by registering at .

Over the past decade, the laboratory has responded to national emergencies, studying highly infectious diseases such as SARS and others. Today it is being called upon in research efforts focusing on the novel coronavirus, SARS-CoV-2, and the disease it causes, COVID-19. And in that lab, researchers are exploring compounds that hold promise as therapeutic agents against the disease and could be grown quickly in host tobacco plants.

That’s right, tobacco. A strain of the reviled plant that has caused fatal diseases for centuries could be the key to quickly mass-producing a preventive agent, treatment or vaccine for COVID-19.

“A protein in the university’s own proprietary portfolio and other compounds from industry sources may be useful against SARS-CoV-2,” said Kenneth Palmer, PhD, director of ���Ǵڳ�’s (CPM).�� “We are currently conducting laboratory research with these compounds that could eventually lead to a therapeutic agent against COVID-19.”

���Ǵڳ�’s (RBL) is housed in the CPM and is part of a network of 12 regional and two national labs that were established with support from the NIH to conduct research with infectious agents. The national labs are located at Boston University and at the University of Texas Medical Branch at Galveston. Regional labs are located at the University of Chicago, Duke University, Boston University and other universities throughout the U.S. The RBL network stands ready in response to public health emergencies and emerging diseases such as the novel coronavirus.

The UofL RBL includes Biosafety Level 3 facilities built to the most exacting federal safety and security standards. The stringently secure facilities protect researchers and the public from exposure to the pathogens being investigated. As part of the RBL network, the UofL RBL is able to respond to needs of researchers, federal agencies and pharmaceutical companies nationwide to conduct research with infectious agents.

Palmer and his research team received samples of SARS-CoV-2 last month and are researching it only in the highly secure confines of the RBL. Covered head to toe in personal protective equipment to prevent self-infection, the researchers now are testing the therapeutic candidates against the disease in cell cultures.

The UofL compound is known as and is co-owned by the university with the National Cancer Institute and the University of Pittsburgh. It is a potent anti-viral protein that possesses microbicidal capabilities. The other compounds are proprietary to their respective companies.

The research goal is to identify the best potential treatment option that could eventually be tested in humans, first at UofL to gauge its safety and efficacy and then later at the University of Pittsburgh and other clinical trial sites to continue to test its effectiveness. Although there are no guarantees, “we believe we could move into human clinical trials by the end of the year,” Palmer said.

That’s where the tobacco plants come in. A large amount of the ultimate therapeutic will be needed for human trials. Kentucky’s historical cash crop is a perfect host to produce the quantities needed.

“The unique quality about studying these compounds in Kentucky is that we can rapidly scale up production of tobacco plants to produce the large amounts of the agent we will need for human testing,” Palmer said. “As people already know, tobacco grows very well in Kentucky.”

Some of the compounds are already showing promise in the laboratory. While the end of the year seems far off in the current coronavirus climate, it is realistic because “SARS-CoV-2 may be with us for a couple of winter seasons. We’d like to have a product that could be tested if the infection comes back in the cold season like influenza does,” Palmer said.

If it does, Palmer and his team will be ready. “We think we will be able to deliver the drug as a nasal spray and hope we can use it as a preventive, pre-exposure treatment before a vaccine could be developed. This will be important for the public and especially for those who are at risk because of their age or pre-existing health conditions or because they work in health care.”

.��